Surgical treatment of metastatic VIPoma: a case report

被引:2
作者
Azizian, Azadeh [1 ]
Koenig, Alexander [2 ]
Hartmann, Amelie [3 ]
Schuppert, Frank [3 ]
Hosseini, Ali Seif Amir [4 ]
Kitz, Julia [5 ]
Ghadimi, Michael [1 ]
机构
[1] Univ Med Ctr Goettingen, Dept Gen Visceral & Pediat Surg, Robert Koch Str 40, D-37077 Gottingen, Germany
[2] Univ Med Ctr Goettingen, Dept Gastroenterol & Gastrointestinal Oncol, Gottingen, Germany
[3] Klinikum Kassel GmbH, Dept Gastroenterol Endocrinol Diabetol & Gen Med, Kassel, Germany
[4] Univ Med Ctr Goettingen, Dept Diagnost & Intervent Radiol, Gottingen, Germany
[5] Univ Med Ctr Goettingen, Inst Pathol, Gottingen, Germany
关键词
case report; metastatic VIPoma; surgery; ISLET; TUMORS;
D O I
10.1177/17562848211051132
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
VIPoma, a neuroendocrine tumour mostly occurring in the human pancreas and producing high levels of vasoactive intestinal peptide, is a rare disease that presents with a wide spectrum of symptoms, including intense diarrhoea, hypokalaemia, and cardiac complications, with life-threatening consequences. In most cases, metastatic lesions are present at VIPoma diagnosis. Treatment options include symptomatic therapy, chemotherapy, radiation and surgery. Due to its low incidence, there are no evidence-based therapy recommendations to date. Here, we present a case of a 39-year-old woman with severe symptoms due to VIPoma of the pancreas with diffuse hepatic metastasis, who underwent simultaneous resection of the primary tumour, extensive liver resection and radiofrequency ablation. The patient was released in good health and was recurrence-free during 12 months surveillance. According to the existing literature and our own experience, surgical procedures appear to be the most promising therapy option for cases with diffuse hepatic metastasis, offering patients relief from their symptoms and (chemo)therapy-free time.
引用
收藏
页数:6
相关论文
共 13 条
  • [1] Abu-Zaid Ahmed, 2014, Hematol Oncol Stem Cell Ther, V7, P109, DOI 10.1016/j.hemonc.2014.03.002
  • [2] Amiri Fateme Shamekhi, 2019, Indian J Endocrinol Metab, V23, P318, DOI 10.4103/ijem.IJEM_105_19
  • [3] Sunitinib for the Treatment of Metastatic Paraganglioma and Vasoactive Intestinal Polypeptide-Producing Tumor (VIPoma)
    Bourcier, Matthew E.
    Vinik, Aaron I.
    [J]. PANCREAS, 2013, 42 (02) : 348 - 352
  • [4] GARDNER JD, 1966, P SOC EXP BIOL MED, V123, P361
  • [5] Iwasaki Mari, 2019, F1000Res, V8, DOI 10.12688/f1000research.18039.1
  • [6] Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide
    Marques, Bernardo
    Monteiro, Ana Raquel
    Martins, Raquel G.
    Couto, Joana
    Rodrigues, Fernando
    Ribeiro, Joao
    [J]. PANCREAS, 2020, 49 (03) : E19 - E20
  • [7] CLINICAL REVIEW 72 - DIAGNOSIS AND MANAGEMENT OF FUNCTIONING ISLET-CELL TUMORS
    PERRY, RR
    VINIK, AI
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (08) : 2273 - 2278
  • [8] CARE guidelines for case reports: explanation and elaboration document
    Riley, David S.
    Barber, Melissa S.
    Kienle, Gunver S.
    Aronson, Jeffrey K.
    von Schoen-Angerer, Tido
    Tugwell, Peter
    Kiene, Helmut
    Helfand, Mark
    Altman, Douglas G.
    Sox, Harold
    Werthmann, Paul G.
    Moher, David
    Rison, Richard A.
    Shamseer, Larissa
    Koch, Christian A.
    Sun, Gordon H.
    Hanaway, Patrick
    Sudak, Nancy L.
    Kaszkin-Bettag, Marietta
    Carpenter, James E.
    Gagnier, Joel J.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2017, 89 : 218 - 235
  • [9] TNM staging of foregut (neuro)endocrine tumors:: a consensus proposal including a grading system
    Rindi, G.
    Kloeppel, G.
    Alhman, H.
    Caplin, M.
    Couvelard, A.
    de Herder, W. W.
    Erikssson, B.
    Falchetti, A.
    Falconi, M.
    Komminoth, P.
    Koerner, M.
    Lopes, J. M.
    McNicol, A-M.
    Nilsson, O.
    Perren, A.
    Scarpa, A.
    Scoazec, J. -Y
    Wiedenmann, B.
    [J]. VIRCHOWS ARCHIV, 2006, 449 (04) : 395 - 401
  • [10] Sandhu S, 2020, VIPOMA